Asarina Pharma AB

Equities

ASAP

SE0011641794

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 15:41:17 17/05/2024 BST			5-day change	1st Jan Change
0.844 ^SEK	+1.69%		-6.01%	-4.09%

02-27	Asarina Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Asarina Pharma AB Reports Earnings Results for the Half Year Ended June 30, 2023	CI

Asarina Pharma AB Publ Reports Earnings Results for the First Quarter Ended March 31, 2020

May 26, 2020 at 07:00 am

Asarina Pharma AB publ announced earnings results for the first quarter ended March 31, 2020. For the first quarter, the company announced operating loss was SEK 21.118 million compared to SEK 10.753 million a year ago. Net loss was SEK 18.369 million compared to SEK 9.430 million a year ago.

Latest news about Asarina Pharma AB

Asarina Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-27	CI
Asarina Pharma AB Reports Earnings Results for the Half Year Ended June 30, 2023	23/08/23	CI
Asarina Pharma's Positive Phase IIa Tourette Syndrome Results to Be Presented At Ticcon, the Virtual National Conference of the Tourette Association of America	05/05/23	CI
Asarina Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2022	27/02/23	CI
Asarina Pharma Completes Recruitment For Clinical Study On Tourette Syndrome	14/10/22	MT
Asarina Pharma Completes Recruitment of Patients to its Phase IIa Clinical Study in Tourette Syndrome	14/10/22	CI
Asarina Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	25/08/22	CI
Asarina Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2022	25/05/22	CI
Asarina Pharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	24/02/22	CI
Asarina Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2021	24/02/22	CI
Asarina Pharma AB Announces That `First Patient First Visit' Has Taken Place in Its Phase Ii A Clinical Study in Tourette Syndrome At Bispebjerg University Hospital, Copenhagen	16/02/22	CI
Asarina Pharma Receives Final Approval for Phase IIa Tourette Study	22/12/21	CI
Asarina Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	25/11/21	CI
Pmdd Phase Iib Study, Including Post-Hoc Analysis Showing ‘Significant Treatment Effect	28/09/21	CI
Asarina Pharma Announces Administrative Backlog At Public Authority Causes Short-Term Delay in Tourette Study	16/09/21	CI
Asarina Pharma AB Publ Reports Earnings Results for the Second Quarter Ended June 30, 2021	19/08/21	CI
Asarina Pharma Reports Topline Results in Phase IIa Menstrual Migraine Study	23/06/21	CI
The US Patent and Trademark Office Grants Asarina Pharma's Patent for Sepranolone for the Treatment of Tourette, Obsessive-Compulsive Disorder and Pathological Gambling	08/06/21	CI
Asarina Pharma AB Receives Approval of CTA for Phase IIa Tourette Study	19/05/21	CI
Asarina Pharma AB Publ Reports Earnings Results for the First Quarter Ended March 31, 2021	18/05/21	CI
Asarina Pharma AB Confirms New Preclinical Study That Sepranolone Suppresses Tics in Tourette Syndrome	11/02/21	CI
Asarina Pharma AB Publ Reports Earnings Results for the Third Quarter Ended September 30, 2020	25/11/20	CI
Asarina Pharma AB Reaches Full Patient Enrolment in Its Phase Iia Menstrual Migraine (Mm) Study	30/09/20	CI
Asarina Pharma AB Publ Reports Earnings Results for the Second Quarter Ended June 30, 2020	19/08/20	CI
Asarina Pharma AB Publ Reports Earnings Results for the First Quarter Ended March 31, 2020	26/05/20	CI

Chart Asarina Pharma AB

Duration

Period

More charts

Company Profile

Asarina Pharma AB (publ), formerly Umecrine Mood, is a Sweden-based biotech company within area of womenâs health. The Companyâs main product is Sepranolone, a treatment for Premenstrual dysphoric disorder (PDD), a form of Premenstrual syndrome (PMS). Sepranolone (UC1010) is an endogenous compound occurring naturally in the brain. Sepranolone inhibits the effects of allopregnanolone, the steroid that causes PMDD. Moreover, Sepranolone is applicable for treatment of menstrual migraine. Additionally to clinical trials with sepranolone, the Company develops a sepranolone analog that is a similar substance, which allows for alternative administration. The Company conducts trials in Europe. The Companyâs main shareholders are Kurma Biofund and The Foundation for Baltic and East European Studies.

Sector

Biotechnology & Medical Research

Calendar

20/05/2024 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ASARINA PHARMA AB	-4.09%	1.76M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	114B
REGENERON PHARMACEUTICALS, INC.	+11.84%	104B
BIONTECH SE	-14.15%	22.41B
ARGENX SE	-1.05%	22.28B
GENMAB A/S	-5.29%	19.07B
WUXI APPTEC CO., LTD.	-38.29%	18B
BEIGENE, LTD.	-4.16%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.28B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.55B

Bio Therapeutic Drugs